Shenzhen YHLO Biotech (SH:688575) Zheng Quan Ri Bao·2026-01-20 09:07Core Insights - Shenzhen YHLO Biotech Co., Ltd. has made significant strides in the field of industry-academia-research collaboration by establishing two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological diagnosis and intelligent diagnostics [2][3] Group 1: Joint Laboratories - The "Neurodiagnosis Joint Laboratory" will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology development, and key equipment research [3] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" will concentrate on AI image recognition systems, microfluidic detection platforms, and the exploration of new biomarkers, aiming to develop key technologies in intelligent diagnostics and precision medicine [3] Group 2: Strategic Goals - Both laboratories aim to convert core research outcomes into marketable products within 3 to 5 years while cultivating innovative and practical talent [3] - The establishment of these laboratories reflects YHLO's commitment to a clinical demand-oriented and industry transformation-focused collaboration logic [3][4] Group 3: Long-term Collaboration - YHLO's Chairman and CEO emphasized that the collaboration with universities is not just about project alignment but also about systematic and institutional long-term cooperation [4] - The joint laboratories are expected to facilitate a full chain from frontier research to technology development, product transformation, and clinical application, ultimately benefiting patients [4][5]